IDEAYA Biosciences (IDYA) risk factors

Item 1A of every IDEAYA Biosciences, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open IDYA in Gloom →

IDEAYA Biosciences' chart, financials and news, free in your browser.Open IDYA in Gloom →

FY2025 10-K risk factors
90 risks7 new11 dropped23 reworded
IDEAYA Biosciences added clinical trial and orphan drug regulatory risks.
Filed Feb 17, 2026
FY2024 10-K risk factors
94 risks
IDEAYA Biosciences relies entirely on unapproved precision medicine and synthetic lethality product candidates in clinical development. The company depends heavily on third-party manufacturers, suppliers, and diagnostic developers for its clinical trials. Substantial additional financing will be required to fund ongoing research, trials, and potential commercialization.
Filed Feb 18, 2025